Drugs for Urinary Incontinence or Retention Flashcards

1
Q

Anticholinergics

A
Darifenacin 
Fesoterodine 
Oxybutynin 
Solifenacin
Tolterodine 
Trospium  
Botulinum Toxin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Sympathomimetics

A

Mirabegron
Pseudoephedrine †
Ephedra †

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Ancillary Drugs

A

Methionine

Bovine Collagen Implant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Overactive Bladder (OAB)

A

Substantial medical and QOL sequelae of OAB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Treatment of Urinary Incontinence typically begins with?

A

Noninvasive approaches such as behavioral therapy, including patient education, fluid management, bladder retraining, pelvic floor exercises, biofeedback, and timed bladder emptying.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

If noninvasive does not work?

A

Surgical procedures and catheterization are appropriate for some patients or add pharmacotherapy when behavioral modification fails.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Most commonly prescribed drugs?

A

Antimuscarinic medications: tolterodine & oxybutynin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Reluctance in nursing home use due to?

A

Lack of efficacy data in these populations, often severe cognitive impairment, and risk of drug-drug interactions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Incontinence [Urge (detrusor overactivity)]
Common Causes
Usual Symptoms
Drug Treatments

A

Strokes, Alzheimer Parkinson disease BPH with overflow

Urgency & frequency, day or night (nocturia)

Anticholinergics: Oxybutynin & Tolterodine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Incontinence [Stress (outlet incompetence)]
Common Causes
Usual Symptoms
Drug Treatments

A

Urological procedures, multigravida, Estrogen deficiency

Minimal urine loss with coughing, sneezing, running, or laughing

Topical estrogen, Alpha-agonists Non-drug method

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Incontinence [Mixed]
Common Causes
Usual Symptoms
Drug Treatments

A

Multiple etiologic factors

Symptoms of urge and/or stress and/or overflow

Focus treatment on predominant symptoms

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Incontinence [Atonic bladder]
Common Causes
Usual Symptoms
Drug Treatments

A

Severe diabetic neuropathy, Stroke

Complete loss of bladder control

Catheterization

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Incontinence [Functional]
Common Causes
Usual Symptoms
Drug Treatments

A

Inability to reach bathroom, changes in mental
status, UTIs, medications

Symptoms of incontinence vary according to type
of external cause

Therapy choice to eliminate cause

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Salivary glands:
Receptors
Effects of Blockage

A

M1, M3, M4

Dry mouth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Cardiac tissue:
Receptors
Effects of Blockage

A

M2

Tachycardia, palpitations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Eye (ciliary muscle, iris)
Receptors
Effects of Blockage

A

M3, M5

Dry eyes, blurred vision

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

GI tract:
Receptors
Effects of Blockage

A

M1, M2, M3

Slowing of transit time (constipation), effects on sphincter tone and gastric acid secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

CNS, brain (cortex and hippo-campus):
Receptors
Effects of Blockage

A

M1, M2, M3, M4, M5

Effects on memory, cognition and psychomotor speed, confusion, delirium, hallucinations, sleep disruption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Bladder (detrusor muscle):
Receptors
Effects of Blockage

A

M2 (opposes β- receptor), M3 (direct effect)

Decreased contraction, urinary retention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Adverse Effects of Anticholinergic Drugs

Peripheral Effects

A
Dry mouth 
Mydriasis 
Constipation
Urinary retention
Tachycardia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Adverse Effects of Anticholinergic Drugs

Central Effects

A
Sedation
Confusion/delirium
Hallucinations
Slowed cognitive function
Sleep disruption
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Tertiary Amines are?

A
Oxybutynin
Tolterodine
Fesoterodine
Solifenacin
Darifenacin
23
Q

Quaternary Amine is?

A

Trospium means want effect CNS.

24
Q

Which has > M3- selectivity?

A

Darifenacin

25
Q

Oral bioavailability Poor:

A

Darifenacin
Oxybutynin
Trospium

26
Q

CYP Metabolism only one with almost no CYP activity?

A

Trospium

27
Q

Trospium & Fesoterodine have rapid

A

Urinary Excretion

28
Q

Solifenacin half life:

A

45–68 hrs

29
Q

Oxybutynin & Tolterodine both have?

A

Short half lives (2hrs), but have extended release formulations.

30
Q

Fesoterodine is rapidly hydrolyzed to?

A

5-hydroxymetghyl-tolterodine; parental drug is not detectable in systemic circulation.

31
Q

Elderly patients may be taking multiple anticholinergics, so monitor for adverse effects:

A

– Urinary retention, especially in BPH
– CV effects may include palpitations, tachycardia, & a prolonged QTc interval
– GI effects: mild constipation to severe obstructions

32
Q

Elderly patients may be taking multiple anticholinergics Contraindications:

A

– Angle closure or narrow-angle glaucoma
– Urinary and gastric obstruction
– Need for mental alertness
– Alzheimer’s type dementia

33
Q

Risk of withdrawal & dry mouth

A

Dry Mouth: Oxybutynin = Tolterodine > Solifenacin & Fesoterodine

34
Q

Botox injections are more successful in patients with?

A

Anticholinergic intolerability as compared to patients with poor medication efficacy.

35
Q

Botox Mechanism:

A

Inhibits vesicular release of excitatory neurotransmitters and axonal expression of other SNARE-complex dependent proteins in the urothelium/suburothelium mediating intrinsic or spinal reflexes thought to cause detrussor overactivity.

36
Q

Sympathetic postganglionic neurons release?

A

Norepinephrine, which activates β3 adrenergic receptors to relax bladder smooth muscle & activates α1 adrenergic receptors to contract urethral smooth muscle.

37
Q
Mirabegron
Receptor binding:
Oral bioavailability:
CYP Metabolism:
Urinary Excretion:
Half-life:
A

β-3 agonist; increases bladder capacity by relaxing detrusor s.m.
≤ 35%; decreased by food
3A4&raquo_space; 2D6; also butylcholinesterase, UGT, & alcohol dehydrogenase
~10% as parental drug
~50 hrs

38
Q
Pseudoephedrine
Receptor binding:
Oral bioavailability:
CYP Metabolism:
Urinary Excretion:
Half-life:
A
Direct & indirect α & β agonist; α>β effects
Almost complete
Minimal
≤ 75%; increase with acidic urine
9-16 hrs, depending on urinary pH
39
Q
Ephedra
Receptor binding:
Oral bioavailability:
CYP Metabolism:
Urinary Excretion:
Half-life:
A
Indirect nonselective α & β agonist
~85%
Minimial
Up to 99%; increase with acidic urine
~5 hrs
40
Q

Mirabegron side effects?

A

– Increase BP; monitoring recommended, especially in hypertensives.
– Tachycardia

41
Q

Pseudoephedrine side effects?

A

– Hypertension, tachyarrhythmia, A-fib
– Insomnia
– Anxiety, feeling nervous, restlessness

42
Q

Ephedra side effects?

A

– Hypertension, tachyarrhythmia, CHF, MI
– Insomnia
– Symptoms of CNS stimulation

43
Q

Have MAOI interaction?

A

Mirabegron
Pseudoephedrine
Ephedra
Check patient drug history

44
Q

Methionine Mechanism & use?

A

• Creates ammonia-free urine by acidifying urine pH
• Used to control odor, dermatitis, and ulceration in
incontinent adults

45
Q

Methionine adverse effects?

A

Most common adverse effects: Drowsiness; nausea and vomiting.

46
Q

Bovine Collagen mechanism & use?

A

For incontinence due to intrinsic sphincter deficiency.
Injected into submucosal tissue of urethra and/or bladder neck & forms a soft cohesive network of fibers increasing tissue bulk around the urethral lumen.

47
Q

Bovine Collagen Adverse Reactions:

A

Urinary retention, hematuria, injection site reaction, worsening incontinence, erythema, urticaria, abscess formation.

48
Q

Management Of Urinary Retention Includes?

A

Assessment of post-void residual urine volume Strengthening of cholinergic-mediated detrussor
muscle contraction

49
Q
Bethanechol 
Receptor binding:
Oral bio-availability:
Metabolism:
Urinary Excretion:
Half-life:
A
Muscarinic agonist in urinary bladder and GI tract
Ionized; doesn’t cross BBB
Poor; % undetermined
Not inactivated by cholinesterases
Undetermined
Short duration: 1 hr orally, 2 hrs s.c.
50
Q
Neostigmine
Receptor binding:
Oral bio-availability:
Metabolism:
Urinary Excretion:
Half-life:
A

Inhibits acetylcholinesterase, augments action of Ach at both muscarinic and nicotinic receptors
Poor, ~2%
Inactivated by cholinesterases & hepatic microsomal enzymes
≤ 70% as parental drug
< 1 hr

51
Q

Bethanechol side effects:

A
– CV: Lightheadedness, Syncope
– GI: Diarrhea, Stomach cramps
– Neurologic: Dizziness
– Ophthalmic: Excessive tear production, miosis
– Renal: Urgent desire to urinate
52
Q

Neostigmine side effects:

A
– AV block
– Bradyarrhythmia
– Cardiac arrest
– Cardiac dysrhythmia
– Hypotension
– Syncope
– Tachycardia
53
Q

Opiate Adverse Effects

A
  • Urinary retention (oral, < 5% ; epidural/intrathecal, ≤ 70%)
  • Cholinomimetic agents such as bethanechol may be helpful to treat urinary retention induced by opioids